Quoin Pharmaceuticals, Ltd.

QNRX

US74907L3006

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 02:35:03 2024-05-16 pm EDT			5-day change	1st Jan Change
0.78 ^USD	+0.52%		-1.89%	-84.10%

May. 09	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 15	Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating	MT

Cellect Biotechnology Ltd. Appoints Yaron Pereg as Chief Development Officer in the Place of Nadir Askenasy

January 30, 2017 at 04:00 pm EST

Cellect Biotechnology Ltd. announced that it appointed Dr. Yaron Pereg as its Chief Development Officer, filling the role vacated by Dr. Nadir Askenasy, who resigned as its Chief Technology Officer.

Latest news about Quoin Pharmaceuticals, Ltd.

Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating	Mar. 15	MT
Quoin Pharmaceuticals Seeks M&A Opportunities	Mar. 14	CI
Transcript : Quoin Pharmaceuticals, Ltd., Q4 2023 Earnings Call, Mar 14, 2024	Mar. 14
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 13	CI
ADRs Close Higher; Dada Nexus Ltd. Climbs 30%	Mar. 06	DJ
ADRs Slump, Quoin Pharmaceuticals Ltd. Declines 48.3%	Mar. 05	DJ
Top Midday Decliners	Mar. 05	MT
Quoin Pharmaceuticals Prices $6.5 Million Public Offering; Shares Fall	Mar. 05	MT
Top Premarket Decliners	Mar. 05	MT
Top Midday Gainers	Mar. 04	MT
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial	Mar. 04	DJ
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	Mar. 04	CI
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	Feb. 08	CI
Quoin Pharmaceuticals, Ltd. announced that it expects to receive $8 million in funding from Alumni Capital LP	Jan. 24	CI
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome	Dec. 18	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Quoin Pharmaceuticals, Ltd., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Quoin Pharmaceuticals, Ltd. Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome	23-10-24	CI
Quoin Pharmaceuticals Ltd. Enters into an Exclusive License and Distribution Agreement with Farma Mondo SA	23-09-13	CI
Quoin Pharmaceuticals Limited Seeks M&A	23-08-03	CI
Transcript : Quoin Pharmaceuticals, Ltd., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-02	CI
Transcript : Quoin Pharmaceuticals, Ltd., Q1 2023 Earnings Call, May 09, 2023	23-05-09
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-08	CI

Chart Quoin Pharmaceuticals, Ltd.

Duration

Period

More charts

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Sector

Biotechnology & Medical Research

Calendar

2024-08-14 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.776 USD

Average target price

5.8 USD

Spread / Average Target

+647.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUOIN PHARMACEUTICALS, LTD.	-84.10%	3.09M
MODERNA, INC.	+33.25%	49.46B
IQVIA HOLDINGS INC.	+1.72%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.68%	18.64B
BIO-TECHNE CORPORATION	+8.13%	13.16B
MEDPACE HOLDINGS, INC.	+29.65%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.33%	12.1B

Other Biotechnology & Medical Research

Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Biotechnology & Medical Research

Cellect Biotechnology Ltd. Appoints Yaron Pereg as Chief Development Officer in the Place of Nadir Askenasy

Latest news about Quoin Pharmaceuticals, Ltd.

Chart Quoin Pharmaceuticals, Ltd.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research